Investigating The Experiences of Patients In Immunotherapy Clinical Trials

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-08-31

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It has been observed before that participation in medical trials has been in favor of specific demographic groups. But research pointing out which trial attributes impact participation positively or negatively is sparse.

This study invites various participants to collect more data on their immunotherapy clinical experiences. The goal is to know which factors always limit how patients participate or complete the medical study they are first interested in.

The data obtained in the trial will be assessed through a variety of demographic lenses to discover patterns that might improve the experience of immunotherapy patients in the future.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

NCT04242095

Malignancy

RECRUITING

Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy

NCT06089967

Cancer Immune-related Adverse Event

COMPLETED

Immunotherapy & Me

NCT03347058

Cancer

COMPLETED NA

Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy

NCT03434912

CTC and Tumor Related Rare Cell

UNKNOWN

A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors

NCT02318394

Advanced Solid Tumors

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immunotherapy Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient has self-identified as planning to participate in an interventional clinical trial using immunotherapy
* Patient has been diagnosed with a type of cancer
* Patient is a minimum of 18 years or older

Exclusion Criteria

* Patient has an ECOG score of 4 or higher
* Patient is not able to provide consistent digital reporting as per study requirements
* Patient does not complete Informed Consent Form

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No